Skip to main content

Blood Loss

2
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
3 programs
1
SevofluranePhase 41 trial
Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated WomenN/A1 trial
RBC unitsN/A1 trial
Active Trials
NCT00614432Completed10Est. Apr 2010
NCT01038557Completed254Est. May 2014
NCT01048658Completed160Est. Aug 2011
Baxter
BaxterCosta Rica - Cartago
2 programs
1
Hemostatic MatrixPhase 4
FlosealN/A
Baxter International
2 programs
FlosealN/A1 trial
Hemostatic MatrixPHASE_41 trial
Active Trials
NCT04058665Completed300Est. Mar 2022
NCT00990288Completed196Est. Aug 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Oregon TherapeuticsSevoflurane
Baxter InternationalHemostatic Matrix
Baxter InternationalFloseal
Oregon TherapeuticsRBC units
Oregon TherapeuticsBlood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women

Clinical Trials (5)

Total enrollment: 920 patients across 5 trials

NCT01048658Oregon TherapeuticsSevoflurane

Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures

Start: Sep 2009Est. completion: Aug 2011160 patients
Phase 4Completed
NCT00990288Baxter InternationalHemostatic Matrix

The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery

Start: Oct 2007Est. completion: Aug 2010196 patients
Phase 4Completed
NCT04058665Baxter InternationalFloseal

Hemostatic Agent Use and Intraoperative Blood Loss in Lumbar Spine Surgery

Start: Jun 2019Est. completion: Mar 2022300 patients
N/ACompleted
NCT01038557Oregon TherapeuticsRBC units

Frozen Red Blood Cell Transfusions in Trauma Patients

Start: Jan 2010Est. completion: May 2014254 patients
N/ACompleted
NCT00614432Oregon TherapeuticsBlood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women

Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women

Start: Jan 2008Est. completion: Apr 201010 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.